RT Journal Article
SR Electronic
T1 EGFR exon in lung cancer: Survival predictors?
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P4169
VO 40
IS Suppl 56
A1 Inês Ladeira
A1 Ana Antunes
A1 Carla Ribeiro
A1 Ana Barroso
A1 Sara Conde
A1 Barbara Parente
YR 2012
UL http://erj.ersjournals.com/content/40/Suppl_56/P4169.abstract
AB EGFR mutations are associated with sensitivity to tyrosine kinase inhibitors(TKI) in patients with NSCLC.Studies point to different outcome to TKI treatment according to exon mutation.Aim:Understand how different EGFR mutations predict TKI response and affect survival.Methods: Records review of NSCLC patients with EGFR study(2006-2011). Epidemiological,clinical and outcome information was analyzed using SPSS19.0(p<0.05).Results: Of 409 patients studied 53 were EGFR-positive. After exclusion of 1 drug-resistant patient(exon20) and patients who did not use TKI or had TKI as 1st therapeutic,22 patients were considered-50%male,67.5±9.8y,59.1%non-smokers.Progression-free survival(PFS) was better in exon 19 mutations(p0.04). Survival after TKI(STKI) was better in 18 and 19 mutated patients (no statistical difference-p0.06).View this table:In non-surgical stages(72.8%), exon 19 mutated patients had better global survival(GS),STKI and PFS than others (p>0.05).View this table:Stages IIIB/IVAssociating patients with exons 18 and 20(described as less predictive of therapeutic outcome) GS29.1, STKI12.2 and PFS8.6 months, all higher than values found for exon21(p>0.05).Conclusions: Exon 19 mutation confered better prognosis to patients treated with TKI. Exons 18 and 20(22,7%) were not associated with worse prognosis than exon21. Although this is a small group we believe that is worth to maintain analysis of the 4 exon mutation.